All GLG News Analyses Filed Under: Cardiology

EPA for the treatment of cadiovascular and CNS related moving disorder.

Niacin is the only medication that we have that will increase good HDL significantly. Side effects have caused many not to use this medication. A flushing free preparation would  likely increase its user dramatically.

Pharmaceutical lawsuits in the United States are costly.  In other places in the world and pharmaceutical lawsuit nearly a unicorn. There are three main players in these actions: The injured, the cause of injury, and the lawyers.

The CorE 64 is the latest in coronary imaging technologies, but it is unclear what the provided results mean and what doctors need to do about them. The results of the initial study presented at the American Heart Association Scientific Sessions sparked an intense debate about the role of coronary computed...

1. The results are intriguing, but the clinical relevance for the large number of patients who could be exposed in the real-life clinical situation is uncertain. 2. The hypotheses for thsi program early-on seem to be supported by the phase 3 data to date, i.e., the nitro-comopounds may have actions...

Though Naproxcinod may have better BP control than naproxyn, what are the long term renal and cardiovascular outcomes?

Platelet inhibition is a surrogate marker We know very little about the correlation between platelet function tests and hard clinical outcomes

These results are encouraging for ranexa.  Ranexa has been a niche drug until now.  There are so many therapies for angina, that it is rare for a patient to be refractory to standard therapy.  I am a practicing cardiologist and I can only recall using this drug on one patient to date. ...

Current standard is plavix, aspirin, and IIbIIIa inhibitor or/and bivalrudin/lovenox/heparin in the setting of acute coronary syndrome(threatened MI) requiring intervention.  It is no surprise that Integrillin  plus plavix works better than plavix alone to inhibit platelets, since they inhibit...

The MERLIN TIMI-36 trial is the largest RCT of Ranexa to date - the size and scope of which would be expected to provide definitive data regarding this drug.  Initial results for the entire enrolled patient population found no benefit (but no danger) from the drug.  With such a large trial,...